Printer Friendly

Articles from Stem Cell Business News (March 12, 2012)

1-16 out of 16 article(s)
Title Author Type Words
Aastrom biosciences opens patient enrollment in Phase 3 clinical trial of CLI therapy. Interview 338
Athersys: $9m private placement. 115
Baxter International launches phase 3 trial for chronic myocardial ischemia. 506
Bioheart announces clinical site for ANGEL trial of LipiCell. 201
Bioheart increases revenue sources, reduces debt and cash burn rate. 107
Brainstorm cell therapeutics to test stem cell therapy for multiple sclerosis. Interview 213
Canadian industry partnership to accelerate development of products to market. Interview 459
Genetics Policy Institute files friend of the court brief in stem cell case. 166
German firms receive funding to develop human liver cells for cell-based therapies. Interview 510
Histogen signs license agreement with Suneva Medical for cell conditioned media-based aesthetic products. 276
ISCO: $5 million financing. 134
Medistem adds kidney, lung failure to stem cell clinical trials in Russia. Interview 281
Medistem licenses Yale's stem cell technology for treatment of type 1 diabetes. Interview 226
Nuvilex says its stem cell technology allows replication without rejection. 230
Proteonomix: private placement of $3.8 m. 148
VistaGen to collaborate with duke scientists on cardiac stem cell technology. Interview 159

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |